Dechra Pharmaceuticals plc reported group revenue results for the six months ended December 31, 2016. For the period, the company reported revenue increased by approximately 34% at constant exchange rate (CER) (56% at actual exchange rate (AER)). Core revenue growth, excluding the benefit from acquisitions, was 7% at CER (AER 22%); growth in the core EU business was 6% at CER (AER 20%), and 10% (AER 31%) in North America.